Curanex Pharmaceuticals Inc (CURX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Curanex Pharmaceuticals reported revenue of $0. Net income was -$4.2M, or -$3.40 per diluted share. Operating activities generated -$10.5M of cash. At fiscal year end, Curanex Pharmaceuticals held $11.6M in total assets against $361,040 in total liabilities, including $5.0M of cash and equivalents.
Open the full interactive Curanex Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Curanex Pharmaceuticals Key Stats
| Share Price | $4.88 |
|---|---|
| Market Cap | $6.9M |
| 52-Week Range | $3.66 – $16.00 |
| Shares Outstanding | 1.4 million (basic, 2026 Q2) |
Curanex Pharmaceuticals Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$4.2M |
| Pre-Tax Income | -$4.2M |
| Net Income | -$4.2M |
| Diluted EPS | -$3.40 |
Curanex Pharmaceuticals Quarterly Results
| 2025 Q2 | 2025 Q3 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$60,346 | -$954,059 | -$3.2M | -$3.3M |
| Diluted EPS | — | -$0.80 | -$2.20 | -$2.40 |
Curanex Pharmaceuticals Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $5.0M |
| Current Assets | $11.2M |
| Total Assets | $11.6M |
| Current Liabilities | $137,030 |
| Total Liabilities | $361,040 |
| Shareholders' Equity | $11.2M |
Curanex Pharmaceuticals Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$10.5M |
| Cash From Financing | $15.3M |
Figures from Curanex Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Curanex Pharmaceuticals financials page for every line item.
Curanex Pharmaceuticals Company Profile
| Ticker | CURX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Jericho, New York |
| Incorporated in | Nevada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0002025942 |
Frequently Asked Questions
What was Curanex Pharmaceuticals' revenue in fiscal 2025?
Curanex Pharmaceuticals (CURX) reported revenue of $0 for fiscal 2025.
What was Curanex Pharmaceuticals' net income in fiscal 2025?
Curanex Pharmaceuticals reported net income of -$4.2M for fiscal 2025.
What was Curanex Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Curanex Pharmaceuticals' diluted EPS was -$3.40 for fiscal 2025 (adjusted for any later stock splits).
What was Curanex Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Curanex Pharmaceuticals reported revenue of $0.
How many shares of Curanex Pharmaceuticals are outstanding?
Curanex Pharmaceuticals reported a weighted average of 1.4 million basic shares outstanding in 2026 Q2.
What is Curanex Pharmaceuticals' market cap?
Based on its latest closing price, Curanex Pharmaceuticals (CURX) has a market capitalization of about $6.9M.
When does Curanex Pharmaceuticals' fiscal year end?
Curanex Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Curanex Pharmaceuticals headquartered?
Curanex Pharmaceuticals lists its business address in Jericho, New York in its SEC filings.